Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 15;37(16):1412–1423. doi: 10.1200/JCO.18.01480

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 3. — Discriminative ability of microRNA (miR)-371a-3p. (A) Receiver operating characteristic curves that discriminate controls (n = 258) from all patients with germ cell tumors (GCTs; n = 522; area under the curve [AUC], 0.966), clinical stage (CS) I only (n = 371; AUC, 0.953), or CS II/III only (n = 151; AUC, 0.996). (B) Sensitivity of miR-371a-3p in all GCTs (n = 522) compared with the classic GCT markers β-human chorionic gonadotropin (bHCG), α-fetoprotein (AFP), and lactate dehydrogenase (LDH) and all three classic markers combined. (C) Same comparison for CS I GCT only (n = 371). (D) Same comparison for CS II/III GCT only (n = 151). (E) Same comparison for seminoma only (n = 323). (F) Same comparison for nonseminoma only (n = 199). Error bars represent the 95% CI. (*) P < .001.